Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) is one of the best inexpensive stocks to buy according to hedge funds. On September 8, BioNTech (NASDAQ:BNTX) and Bristol Myers Squibb presented positive interim data from a global randomized Phase 2 trial of their investigational bispecific antibody, pumitamig (BNT327/BMS986545). The trial evaluated pumitamig in combination with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC).

The data, consistent with a prior Phase 2 trial in China, showed encouraging anti-tumor activity and a manageable safety profile. The results were presented at the IASLC 2025 World Conference on Lung Cancer in Barcelona. The interim analysis, with a data cut-off date of August 7, included 43 patients with previously untreated ES-SCLC. The safety profile was manageable, with a discontinuation rate of 14%.

Pumitamig is a bispecific antibody that combines 2 mechanisms: PD-L1 checkpoint inhibition and the neutralization of VEGF-A. This dual action is intended to restore the immune system’s ability to fight cancer and cut off the tumor’s blood supply. The positive results from the Phase 2 trial support the ongoing global pivotal Phase 3 trial, ROSETTA LUNG-01, which is comparing pumitamig plus chemotherapy against standard-of-care treatment in first-line ES-SCLC. In 2025, pumitamig received Orphan Drug designation from the US FDA for the treatment of small-cell lung cancer.

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.

BioNTech (NASDAQ:BNTX) is a biotechnology company that develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.